Psychiatry

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

A new study from ATS showed an early symptom of Alzheimer disease is more prevalent in older patients with moderate OSA.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

David Kingdon, MD, FRCPsych, professor of mental health care delivery at the University of Southampton, sat down with MD Magazine at APA 2019 to discuss recent advances in psychosis.

Sleep apnea is associated with pulmonary, cardiovascular, psychiatric, neurologic, and weight-related effects. Primary care physicians need to monitor sleep health more.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

In a study presented at Digestive Disease Week 2019, results indicated the risk of developing Parkinson's disease was 3 times higher in patients who had appendectomies.

Mental health disorders are highly prevalent in certain patients with COPD—and their effect can limit lung function therapy benefit.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

Patients diagnosed with psoriasis face a nearly three-fold greater risk of developing anxiety disorders.

Assaults have become common in emergency departments. Organizers and individuals are calling on caregivers and administrators to collaborate on real solutions.

The investigative drug SEP-363856 has been evidenced in a phase 2 trial to reduced hospitalized patient symptoms and severity.

Esketamine nasal spray is currently relegated to a specific depression patient population, but that may not be for long.

From 2010 to 2017, there was an increase of over 30% in the number of commercially insured children being diagnosed with ADHD.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

The FDA approved the Monarch electronic Trigeminal Nerve Stimulation based on the findings of a trial involving children aged 7-12 years old.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.

A new study shows that a history of anxiety and depression drive suicidal thoughts in students, but having a significant other may limit such thoughts.

Investigators reviewed 347 published articles and found that physician suicide, while a significant problem, is poorly understood and identified multiple possible interventions that could help.

Sleep habits are an overlooked aspect of primary care visits, despite the prevalence and burden of conditions such like insomnia on the general population.

Both long-acting injectable treatments produced statistically significant and clinically meaningful improvements.